Ruling Will Thwart Biosimilar Drug Market

By , 11/30/15 The Europeanization of U.S. drug pricing that Scott Gottlieb warns about in his op-ed (“The Coming Government Takeover of Drug Pricing,” Nov. 23) already has begun. He warns of “reference pricing,” in which the government lumps together drugs that “bureaucrats feel are similar enough that they can be used in place...

Congress Should Say No to Cutting Drug Subsidies for Low-Income Seniors

President Barack Obama and congressional appropriators are looking for savings to offset new federal spending programs.  One proposal on the table – drawn from the president’s budget plan – would disproportionately impact low-income seniors who rely on prescription medications for serious medical conditions. The measure, estimated to save $8.9 billion over ten years, would...

CMS Rule Undermines Real Cost Savings For Consumers & Could Cripple Fledgling U.S. Biosimilar Market

The Obama administration is proposing a Medicare payment rule that would have the effect of clamping price controls on biosimilar drugs, extending destructive pricing policies to a potentially vibrant 21st century life sciences industry. The Centers for Medicare and Medicaid Services (CMS) has proposed a rule that would guide how Medicare pays for a...

A Bad-Actor, Not A Pharmaceutical Innovator, Causes Outrage Over Drug Prices

A profiteer masquerading as a pharmaceutical company executive has set the Internet afire with his 5,000% price increase for a rare but important drug used by AIDS and some cancer patients. Martin Shkreli, a 32-year-old former hedge fund manager, cornered the market on Daraprim, a drug used to treat a life-threatening parasitic infection. His...